AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich

28-Feb-2008

Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's proprietary ...

more

30-Nov-2001

MorphoSys AG (Neuer Markt: MOR) today announced the development and release of a new proprietary antibody library, HuCAL® GOLD. The library is to be presented at the 12th IBC Antibody Engineering conference in San Diego, California. Initial results show that the new library and related screening ...

more

Preferred Access to one of World´s Largest Human tissue banks

27-Sep-2001

MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today an Agreement with Oridis Biomed Forschungs- und Entwicklungs GmbH, Graz, Austria, that will provide MorphoSys with preferred access to one of the world’s largest human tissue banks. The goal of the collaboration is ...

more

18-Sep-2001

MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today that a court in San Diego has granted its motion to dismiss a second attempt by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council, The Scripps Research Institute and Stratagene to ...

more

21-Mar-2001

MorphoSys (Neuer Markt: MOR) today announced its financial results for the full year 2000. As published on February 8, 2001, the Company adopted U.S. Securities and Exchange Commission`s Staff Accounting Bulletin 101 (SAB 101) in the 4th quarter 2000, and for comparability with previous years, ...

more

12-Feb-2001

MorphoSys (Neuer Markt: MOR), the Munich-based bio-pharmaceutical company, today announced the achievement of the first milestone in the therapeutic part of its collaboration with Bayer. The milestone, the delivery of a tailored, high affinity HuCALâ antibody for an undisclosed target, triggered ...

more

15-Dec-2000

MorphoSys AG (Neuer Markt: MOR) announced the successful installation of MorphoSys’ fully automated antibody generation system AutoCALTM at the DuPont Pharmaceuticals research facility in Wilmington, DE/USA. AutoCALTM is MorphoSys’ proprietary robotic system that allows high throughput screening ...

more

12-Dec-2000

Professor Andreas Plückthun, co-founder and member of the supervisory board of MorphoSys AG (Neuer Markt: MOR) has received an award from the Karl-Heinz-Beckurts-Foundation for his outstanding scientific as well as commercial achievements in the field of synthetic antibody generation. This is one ...

more

07-Dec-2000

MorphoSys (Neuer Markt: MOR), the Munich-based biopharmaceutical company, has announced the development of a new screening method for use in conjunction with its proprietary HuCAL© technology. The method, cysteine mediated phage display, called CysDisplay™, was presented at the 11th IBC Antibody ...

more

30-Nov-2000

MorphoSys AG (Neuer Markt: Mor) and ProChon Biotech Ltd. announced today the accomplishment of the first milestone in their collaboration which started in June 2000. MorphoSys has delivered a series of human HuCALâ antibodies which proved to block the function of the ProChon target. The target is ...

more